Oncology
McKesson Restructures Business Segments to Focus on High-Growth Healthcare Areas
McKesson Corporation is reorganizing its reporting structure to enhance strategic alignment and transparency, focusing on accelerating growth in oncology, multispecialty, and biopharma services while optimizing portfolio management for long-term shareholder value.
Cancer Patients Face Nutritional Challenges During Treatment as Companies Develop New Therapies
Cancer patients struggle with increased nutritional needs during treatment while facing eating difficulties, highlighting the importance of dietary management alongside medical advancements.
Lantern Pharma Completes Successful Phase 1a Trial for AI-Driven Cancer Drug LP-184
Lantern Pharma's AI-developed oncology drug LP-184 demonstrates promising safety and efficacy in Phase 1a trial, showing disease control in 48% of evaluable patients with advanced solid tumors and paving the way for targeted cancer treatments.
Oncotelic Therapeutics Reports Two Years of Clinical Progress Across Oncology and Rare Disease Programs
Oncotelic Therapeutics has achieved significant clinical milestones over the past two years, advancing multiple late-stage programs including OT-101 for pancreatic cancer and OXi4503 for AML/MDS, positioning the company to address multi-billion-dollar markets with high unmet medical needs.
Kairos Pharma to Host Key Opinion Leader Event on Phase 2 Prostate Cancer Trial Results
Kairos Pharma will present interim efficacy results from its Phase 2 trial of ENV105 in advanced prostate cancer, potentially addressing critical drug resistance challenges in oncology treatment.
Lantern Pharma CEO Discusses AI-Driven Cancer Drug Development on BioMedWire Podcast
Lantern Pharma's CEO Panna Sharma outlines the company's progress in using artificial intelligence to accelerate cancer drug development and transform oncology treatment approaches.
Helix BioPharma to Present Clinical Trial Progress and NASDAQ Uplisting Plans at Investor Summit
Helix BioPharma will present its Phase Ib/II clinical study for non-small cell lung cancer treatment and planned NASDAQ uplisting at the Q3 2025 Investor Summit, highlighting strategic moves to advance oncology therapies and access global capital markets.
Oncotelic Therapeutics Highlights CEO's Track Record and Clinical Pipeline Advancements
Oncotelic Therapeutics showcases CEO Dr. Vuong Trieu's substantial patent portfolio and successful drug development history while updating progress on its oncology and immunotherapy pipeline.
Fifty 1 Labs Subsidiary Publishes Key Oncology Real-World Evidence Research
Fifty1 AI Labs' publication on transportability methods in oncology real-world evidence demonstrates how AI-driven frameworks can bridge data gaps and improve global access to life-saving therapies in a market projected to reach $3.51 billion by 2035.
Kairos Pharma to Present Initial Phase 1 Data for ENV105 Lung Cancer Treatment at World Conference
Kairos Pharma Ltd. will present initial Phase 1 data for its ENV105 combination therapy targeting drug-resistant non-small cell lung cancer at the World Lung Cancer Conference, potentially addressing significant unmet medical needs in oncology treatment.
Study Links Head Injuries to Increased Brain Cancer Risk, Driving Treatment Research
A Mass General Brigham study of 75,000 patients reveals traumatic brain injuries elevate malignant brain tumor risk, highlighting the importance of ongoing treatment development by companies like CNS Pharmaceuticals Inc.
Oncotelic Therapeutics Highlights Robust Oncology Pipeline and CEO's Patent Portfolio
Oncotelic Therapeutics showcases its clinical-stage oncology and immunotherapy pipeline, including multiple late-stage candidates and rare disease programs, while emphasizing CEO Dr. Vuong Trieu's extensive intellectual property contributions that underpin the company's competitive strategy.
Lantern Pharma Unveils AI Module to Predict Cancer Treatment Efficacy
Lantern Pharma has developed an artificial intelligence module that enhances predictive capabilities for cancer drug combinations, potentially accelerating personalized oncology treatments and improving clinical success rates.
Nerve Damage Identified as Unexpected Cause of Cancer Immunotherapy Resistance
A multinational research team has discovered that cancer-induced nerve damage contributes to immunotherapy resistance, potentially opening new treatment avenues for patients.
Blocking Brain Damage from Glioblastoma May Slow Tumor Growth and Extend Cognitive Function
New research from University College London suggests that preventing brain damage caused by glioblastoma could significantly slow tumor progression and preserve cognitive function longer in patients.
Lantern Pharma Advances Oncology Pipeline with AI-Driven Clinical Progress and Extended Financial Runway
Lantern Pharma reports significant clinical trial advancements and AI platform enhancements while maintaining strong financial discipline, positioning the company for continued oncology drug development through mid-2026.
Calidi Biotherapeutics Prices $6 Million Public Offering to Advance Clinical-Stage Cancer Therapies
Calidi Biotherapeutics has priced a $6 million public offering to fund development of its Redtail platform, which uses engineered oncolytic viruses to deliver genetic medicines to metastatic cancer sites, addressing high unmet medical needs in oncology.
Atlanta Radiation Oncologist Ahmed Ali Honored as 2025 Castle Connolly Top Doctor
Dr. Ahmed Ali's recognition as a 2025 Castle Connolly Top Doctor highlights his contributions to radiation oncology and the advanced treatments he offers for various cancers.
Ascentage Pharma Advances Global Phase III Trial for Lisaftoclax in Higher-Risk MDS Treatment
Ascentage Pharma's GLORA-4 Phase III trial of lisaftoclax, a potential breakthrough for higher-risk myelodysplastic syndrome (MDS), receives FDA and EMA clearance, marking a significant step towards addressing a critical unmet medical need in oncology.
Creative Biolabs Enhances Gene Therapy Research with Expanded Liposomal Drug Delivery Services
Creative Biolabs has expanded its liposomal drug delivery services to support advancements in gene therapy, oncology, and molecular medicine, offering customized solutions for research institutions and pharmaceutical industries worldwide.
Lantern Pharma Reports Significant Q2 2025 Achievements and Expands AI Platform
Lantern Pharma announces Q2 2025 results with complete responses in oncology trials and advancements in its AI platform, marking a pivotal step in cancer treatment innovation.
Intensity Therapeutics Pioneers New Cancer Treatment with Minimal Side Effects
Intensity Therapeutics is advancing a novel cancer treatment that directly targets tumors with minimal side effects, offering hope for patients with refractory solid tumors.
Calidi Biotherapeutics Inc. Reports Q2 2025 Financial Results and Advances in Oncology Research
Calidi Biotherapeutics Inc. (NYSE American: CLDI) has reported its Q2 2025 financial results, showcasing a reduced net loss and significant progress in its oncology research, including FDA Fast Track Designation for its CLD-201 treatment in soft tissue sarcoma.
Lantern Pharma Inc. Completes Japanese Enrollment for LP-300 Phase 2 HARMONIC(TM) Trial Ahead of Schedule
Lantern Pharma Inc. has successfully completed patient enrollment in Japan for its Phase 2 HARMONIC(TM) trial targeting never-smoker non-small cell lung cancer patients, a significant step towards addressing a critical unmet medical need.
Soligenix Inc. Highlighted for Innovation in Rare Disease Treatment
Soligenix Inc.'s inclusion in a NetworkNewsWire editorial highlights its HyBryte(TM) platform's potential to address the urgent need for effective therapies in rare diseases, particularly cutaneous T-cell lymphoma, showcasing a commitment to domestic innovation and support for underserved patient populations.
ARTBIO Strengthens Leadership with Strategic Board Appointments to Advance Cancer Therapies
ARTBIO enhances its board with four industry veterans to propel its innovative alpha radioligand therapies, marking a pivotal step in its mission to revolutionize cancer treatment.
Lantern Pharma Inc. Unveils AI Tool to Predict Cancer Drug Combination Efficacy
Lantern Pharma Inc. introduces an AI-powered module to predict the effectiveness of cancer drug combinations, marking a significant advancement in personalized oncology treatment.
Lantern Pharma's Starlight Therapeutics Receives FDA Clearance for GBM Combination Trial
Starlight Therapeutics, a subsidiary of Lantern Pharma, has been cleared by the FDA to begin a Phase Ib/2a clinical trial for a novel combination therapy targeting glioblastoma multiforme, a move that could significantly impact treatment options for this aggressive brain cancer.
Soligenix Inc. Advances Rare Disease Treatment with HyBryte Platform, Highlighting Growing Need in Aging Population
Soligenix Inc. is making strides in treating cutaneous T-cell lymphoma, a rare skin cancer affecting older adults, underscoring the urgent need for innovative treatments in the face of an aging population and the prevalence of rare diseases.
Soligenix Inc. Advances in Treating Rare Skin Cancer with HyBryte Platform
Soligenix Inc.'s progress with its HyBryte platform for treating cutaneous T-cell lymphoma highlights the critical need for innovative therapies in addressing rare diseases among the aging population.